UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2020 Earnings Conference Call February 25, 2021 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - CEO Anthony Doyle - CFO Bill Sheridan - Chief Medical Officer Megan Sniecinski - Chief Business Officer Charlie Gayer - Chief Commercial Officer Conference Call Participants Jessica Fye - JPMorgan Brian Cheng - Bank of America David Dai - Barclays Maury Raycroft - Jefferies Operator Ladies and gentlemen, thank you f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ______________________ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charte ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2020 Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants John Bluth - Senior Vice President, Investor Relations & Corporate Communications Jon Stonehouse - Chief Executive Officer Charlie Gayer - Chief Commercial Officer Megan Sniecinski - Chief Business Officer Bill Sheridan - Chief Medical Officer Anthony Doyle - Chief Financial Officer Conference Call Participants Tara Bancroft - Piper Sandler Jon Wolleben - JMP Securities Serge Bela ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________. Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (Stateorotherjurisd ...